Combination immunotherapy may raise response rate in mRCC – ModernMedicine
|
Combination immunotherapy may raise response rate in mRCC
ModernMedicine Combination treatment built on immune checkpoint inhibitor therapy showed promising clinical and immunologic activity in patients with metastatic renal cell carcinoma (mRCC) in an early phase I clinical trial, reported investigators from the University … |
